Genetic mutation test kit SuperARMS®

for EGFR mutationsbloodfluorescence

Currently, there are several EGFR-TKIs approved for NSCLC (Non-Small Cell Lung Cancer) targeted therapy, including first-generation TKIs: gefitinib and erlotinib, second-generation TKI: afatinib, and third-generation TKI: osimertinib. In order to select the right patients for these therapies, it is essential to detect EGFR mutation status before taking any treatment decision. NSCLC tissue testing has been applied to EGFR mutations detection for years. However, up to 25% of patients with advanced or metastatic NSCLC do not have an available or sufficient tumor tissue sample for this method of testing. Moerover, the demand for dynamic monitoring of EGFR mutation status is increasing steadily and substantially. The ctDNA (circulating tumor DNA) obtained from blood samples could be used for the assessment of EGFR mutation status when tissue sample is not available. SuperARMS® EGFR kits are highly sensitive real-time PCR-based tests designed to identify ctDNA EGFR mutations in plasma samples of patients with advanced or metastatic NSCLC. The kits adopt the innovative ADx-SuperARMS technology which was upgraded from ADx-ARMS technology. Its optimized reaction system can rapidly and accurately detect a low percentage of mutant ctDNA in a background of wild-type DNA. EGFR T790M Mutation Detection Kit Real-time PCR Assay to detect EGFRT790M Mutation in plasma samples One Tube – two fluorescent labeled: FAM T790M Mutation HEX – Internal Control Analytical sensitivity: 0,2% mutant allele Real-time PCR Assay to detect 42 EGFR Mutation in plasma samples